Known targets — ChEMBL curated mechanism
ACHECHKACHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGHRH2OPRM1
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | SNCA | P37840 | 2/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 6/20 | 0.36 |
| ▸ | TRAP1 | Q12931 | 2/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iodide SCHEMBL3853743 | 0.95 | HIF1A (0.71) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Hydrochloric Acid SCHEMBL28126570 | 0.95 | HIF1A (0.71) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL8374722 | 0.89 | HIF1A (0.62) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL8605602 | 0.89 | HIF1A (0.62) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL8374029 | 0.89 | HIF1A (0.62) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL8371265 | 0.89 | HIF1A (0.62) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL8374635 | 0.89 | HIF1A (0.62) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| SCHEMBL8376828 | 0.89 | HIF1A (0.62) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL2447020 | 0.87 | HIF1A (0.94) | HIF1AALDH1A1CYP1A2CYP2D6TSHR | |
| Bromide SCHEMBL286655 | 0.86 | HIF1A (0.58) | HIF1AALDH1A1CYP1A2CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112375118-A | Method for preparing cholesterol and derivatives thereof by taking phytosterol as raw material | 湖南科瑞生物制药股份有限公司 | 2021-02-19 | — | — | CN | claimed |
| CN-112358523-A | Method for removing triphenylphosphine oxide | 湖南科瑞生物制药股份有限公司 | 2021-02-12 | — | — | CN | claimed |
| US-20170129874-A1 | NOVEL IMPROVED PROCESS FOR PREPARING A TRIAZOLE ANTIFUNGAL AGENT | VIRUPAKSHA ORGANICS LTD (IN) | 2017-05-11 | — | — | US | claimed |
| US-5214129-A | Amidation of a protected amino acid by an di-O-protected dihydroxy-containing amine and coupling with a carboxylic acid; deprotecting; renin inhibitors; hypotensive agents | ABBOTT LABORATORIES (US) | 1993-05-25 | — | — | US | claimed |
| EP-4683957-A1 | STRUCTURAL ADHESIVES CURED BY POLYCARBONATE | Zephyros, Inc. (US) | 2026-01-28 | — | — | EP | disclosed |
| WO-2024197010-A1 | STRUCTURAL ADHESIVES CURED BY POLYCARBONATE | ZEPHYROS, INC. (US) | 2024-09-26 | — | — | WO | disclosed |
| CN-118373846-A | Cerium (III) -based metal halide transparent glass scintillator and preparation method and application thereof | 中国计量大学 | 2024-07-23 | — | — | CN | disclosed |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2024-01-18 | — | — | US | disclosed |
| EP-4225447-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076625-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2021262426-A9 | ADAMANTANE AMIDES AND THIOAMIDES FOR THE TREATMENT OF EBOLAVIRUS INFECTION | ARISAN THERAPEUTICS INC. (US) | 2022-03-17 | — | — | WO | disclosed |
| CN-108699098-B | C-glucoside derivative having fused benzene ring or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition comprising same | 第一药品株式会社 | 2022-01-25 | — | — | CN | disclosed |
| US-4725583-A | ANTIHYPERTENSIVE | ABBOTT LABORATORIES (US) | 1988-02-16 | — | — | US | disclosed |
| EP-0229667-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1987-07-22 | — | — | EP | disclosed |
| US-4665189-A | LEUKOTRIENE ANTAGONISTS | LILLY INDUSTRIES LIMITED (GB) | 1987-05-12 | — | — | US | disclosed |
| EP-0201823-A2 | Novel intermediates for the production of pharmaceuticals | LILLY INDUSTRIES LIMITED (GB) | 1986-11-20 | — | — | EP | disclosed |
| EP-0189203-A2 | Peptidylaminodiols | ABBOTT LABORATORIES (US) | 1986-07-30 | — | — | EP | disclosed |
| EP-0134111-A1 | Araliphatic sulphides,sulphones and sulphoxides and their pharmaceutical use | Lilly Industries Limited (GB) | 1985-03-13 | — | — | EP | disclosed |
| US-4305876-A | CULTURE PRODUCT INTERMEDIATE IN THE PREPARATION OF VITAMINS E AND K | HOFFMANN-LA ROCHE, INC. (US) | 1981-12-15 | — | — | US | disclosed |
| US-4138289-A | ASYMMETRIC HYDROGENATION BY MICROORGANISM, FERMENTATION | HOFFMANN-LA ROCHE INC. (US) | 1979-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170129874-A1 | NOVEL IMPROVED PROCESS FOR PREPARING A TRIAZOLE ANTIFUNGAL AGENT | ERG28, CYP51A1, CYP4F11 | HIF1A 1790/4885ALDH1A1 3171/4885CYP1A2 24/4885 |
| US-20240018161-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HIF1A 3879/4885ALDH1A1 4077/4885CYP1A2 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.